ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Cyclophosphamide

Also written as “cyclophosphamide”, “Cyclophosphamide,Fludarabine” and “Cytoxan”.

Its studies are mostly in Breast Neoplasms · Multiple Myeloma · Lymphoma, Large B-Cell, Diffuse · Leukemia, Lymphocytic, Chronic, B-Cell · Carcinoma, Non-Small-Cell Lung, led by 28 companies.

Drug pageCyclophosphamide: every studyMany companies study it; this page follows only the 70 they lead. All 1,538 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jan 4, 201170 company-led studies, 25 open or runningNext primary completion: Jan 14, 2027 (early phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche151 open or runningphase 4since Jan 4, 2011Oct 16, 2007Feb 28, 2028phase 2 · NCT04931342
Beijing Biotechits history only99 open or runningphase 2since Apr 5, 2026Mar 14, 2026Feb 18, 2027phase 1 · NCT07480941
ImmunoVaccine Technologies, Inc. (IMV Inc.)its history only63 open or runningphase 2since Dec 12, 2014Dec 12, 2014none ahead
Amgenits history only40 open or runningphase 2since Jul 5, 2000Jul 5, 2000none ahead
Sanofiits history only40 open or runningphase 3since Jul 11, 2001Jul 11, 2001none ahead
Takedaits history only41 open or runningphase 2since Jul 25, 2007Jul 25, 2007none ahead
Allogene Therapeuticsits history only32 open or runningphase 2since Dec 8, 2022Dec 8, 2022Dec 2027phase 2 · NCT06500273
Bristol-Myers Squibbits history only21 open or runningphase 2since Dec 22, 2016Dec 22, 2016Mar 15, 2029phase 1 · NCT07115745
Hangzhou Huasai Biomedicineits history only22 open or runningphase 1since Jul 22, 2025Jul 22, 2025Aug 30, 2027phase 1 · NCT07105176
Rampart Healthits history only21 open or runningphase 2since Aug 9, 2019Aug 9, 2019none ahead

Also a collaborator on its studies: Natera, Incyte, AbbVie and Johnson & Johnson.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 16, 2007First study: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellFirst studyNCT00545714 · 86 enrolled · Spain
  2. Jul 16, 2008Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT00718549 · 128 enrolled · Belarus, Poland
  3. Oct 15, 2008Phase 2 study in Breast NeoplasmsNCT00773695 · 150 enrolled · Norway
  4. Dec 17, 2010Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT01263704 · 42 enrolled · Israel
  5. Jan 4, 20112 phase 4 studies in Leukemia, Lymphocytic, Chronic, B-CellNCT01271010, NCT01283386
  6. Feb 8, 2011Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellNCT01292603 · 240 enrolled · Argentina, Australia, Brazil and more
  7. Jul 23, 2012Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT01649856 · 572 enrolled · Algeria, Argentina, Belgium and more
  8. Feb 4, 2014Phase 2 study in Lymphoma, Non-HodgkinNCT02055820 · 267 enrolled · United States, Australia, Austria and more
  9. Mar 23, 2015Phase 4 study in Breast NeoplasmsNCT02419742 · 110 enrolled · India
  10. Aug 24, 2015Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT02533401 · 34 enrolled · Argentina, Venezuela
  11. Nov 12, 2015Phase 1 study in Breast NeoplasmsNCT02605915 · 98 enrolled · United States
  12. Feb 23, 2016Phase 2 study in Arthritis, RheumatoidNCT02693210 · 161 enrolled · Australia, Belgium, Canada and more
  13. Mar 8, 2021Phase 1 study in Lymphoma, Large B-Cell, DiffuseNCT04790903 · 50 enrolled · United States, France, Italy and more
  14. Jun 9, 2021Phase 2 study in Ovarian NeoplasmsNCT04931342 · 176 enrolled · United States, Australia, Canada and more

Ahead

  1. Feb 28, 2028Primary completion: phase 2 study in Ovarian NeoplasmsNCT04931342

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 15 Hoffmann-La Roche leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04931342Ovarian Neoplasms · United States, Australia, Canada and more2Active, not recruitingFeb 28, 2028176
NCT04790903Lymphoma, Large B-Cell, Diffuse · United States, France, Italy and more1TerminatedMay 21, 202450
NCT02693210Arthritis, Rheumatoid · Australia, Belgium, Canada and more2CompletedAug 2002161
NCT02605915Breast Neoplasms · United States1CompletedNov 13, 201998
NCT02533401Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Venezuela2CompletedDec 201434
NCT02419742Breast Neoplasms · India4CompletedJun 24, 2021110
NCT02055820Lymphoma, Non-Hodgkin · United States, Australia, Austria and more2CompletedJun 28, 2017267
NCT01649856Lymphoma, Large B-Cell, Diffuse · Algeria, Argentina, Belgium and more3CompletedOct 21, 2014572
NCT01292603Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Australia, Brazil and more1CompletedMay 7, 2014240
NCT01283386Leukemia, Lymphocytic, Chronic, B-Cell · Russian Federation4TerminatedMar 16, 201626
NCT01271010Leukemia, Lymphocytic, Chronic, B-Cell · Russian Federation4TerminatedMay 4, 201689
NCT01263704Leukemia, Lymphocytic, Chronic, B-Cell · Israel2CompletedApr 3, 201742
NCT00773695Breast Neoplasms · Norway2CompletedNov 9, 2022150
NCT00718549Leukemia, Lymphocytic, Chronic, B-Cell · Belarus, Poland3CompletedSep 14, 2015128
NCT00545714Leukemia, Lymphocytic, Chronic, B-Cell · Spain2CompletedMay 20, 201686

How it is read

Names in the registry

  • “Cyclophosphamide”, 74 entries
  • “cyclophosphamide”, 9 entries
  • “Cyclophosphamide,Fludarabine”, 4 entries
  • “Cytoxan”, 3 entries
  • “CHOP”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.